Targovax to Present at the ESGCT/ISSCR Stem Cells & Gene

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Targovax to Present at the ESGCT/ISSCR Stem Cells & Gene Therapy Symposium

OSLO, Norway, Oct. 17, 2016 (GLOBE NEWSWIRE) -- Targovax (OSE: TRVX, or "the Company"), a clinical stage company developing targeted immunotherapy treatments for cancer patients, announces that the Company will be presenting at the Changing the Face of Modern Medicine: Stem Cells & Gene Therapy symposium, hosted by the European Society of Gene and Cell Therapy (ESGCT) and the International Society for Stem Cell Research (ISSCR).

  • Session name: SESSION 6c: Cancer gene therapy
  • Presentation title: OR52: Anti-tumor potency of cancer vaccine ONCOS-102 in the treatment of malignant mesothelioma in pre-clinical and clinical studies
  • Date: 21 October 2016
  • Time: 09:00 CET
  • Participants: Lukasz Kuryk (Senior Research Scientist, Targovax)
  • Venue: Firenze Fiera Congress Center, Florence, Italy

For further information, please contact:
Gunnar Gårdemyr, CEO
Phone: +46 73 083 77 79
Email: ggardemyr@targovax.com

Øystein Soug, CFO
Phone: +47 90 6565 25
Email: oystein.soug@targovax.com

Media and IR enquires:
Jan Petter Stiff - Crux Advisers (Norway)
Phone: +47 995 13 891
Email: stiff@crux.no

Julia Phillips/Simon Conway - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax@fticonsulting.com

About Targovax

Arming the patient's immune system to fight cancer

Targovax (OSE: TRVX) is a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients. Targovax has a broad and diversified immune therapy portfolio and aims to become a world leader in its area. The company is currently developing two complementary and highly targeted approaches in immuno-oncology.

ONCOS - 102 is a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes targeting solid tumors. This treatment is designed to reactivate the immune system's capacity to recognize and attack cancer cells.

TG01 and TG02 are part of a peptide-based immunotherapy platform targeting the difficult to treat RAS mutations found in more than 85% of pancreatic cancers, 50% of colorectal cancer and 20-30% of all cancers. Targovax is working towards demonstrating that TG vaccines will prolong time to cancer progression and increase survival.

These product candidates will be developed in combination with multiple treatments, including checkpoint inhibitors in several cancer indications. Targovax also has a number of other cancer immune therapy candidates in the early stages of development.

In July 2016 the Company listed its shares on Oslo Axess, securing funding for further development of the Company's ongoing and planned trials.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AEVEX Facing Class Action: Deadline Looms for Investors

Updated Category News Views 7

The Clock is Ticking for AVEX Investors News flash, folks: If you bought into AEVEX Corp. (NYSE: AVEX) between mid-April and early June this year, you might have a legal gold mine on your hands—or at least a shot to join a class action that could knock some dollars back into your pocket. Mark it on your calendar—October 20, 2026, is the last call to toss your hat in...

Continue Reading
Tenant Improvement: Key to Adapting Lease Spaces

Updated Category News Views 0

Adapting Space or Adapting Business? Here's the thing that keeps popping up in commercial real estate: tenant improvement construction. This isn't just modifying a structure—it's about rethinking how businesses operate within a certain space. The HelloNation article gives you the lowdown straight from Bradley Quakenbush of White Oak Commercial Group. When businesses...

Continue Reading
Match2 Enhances HR Tech: Unified Talent Profile System

Updated Category News Views 7

Revolutionizing Talent Matching with Match2's Latest Upgrades In the churn of today's recruiting jungle, candidates and employers have been grappling with disjointed systems and outdated approaches. Well, Match2 is cutting through that noise with some hefty upgrades. It's got some new toys in the shed—specifically, a beefed-up Universal Candidate Profile™ and an...

Continue Reading
AAI Rolls Out Agency Gauge: AI-Driven Insights Platform

Updated Category News Views 10

Bringing Artificial Intelligence to the Insurance Table Affordable American Insurance (AAI) is shaking things up in the insurance world with their new tool, Agency Gauge. Picture this: you're running an independent agency, neck-deep in data, and this AI-powered marvel swoops in and turns those confusing numbers into actionable business insights. It's like having a wise...

Continue Reading
eGlint's Rapid Tech Revolutionizes Proteomics with Win

Updated Category News Views 0

A Game-Changer in Proteomics Now ain't this something—eGlint just scooped up the 2026 BioTools Innovator Grand Prize, waving a big ol' $250,000 check around and claiming the biotech spotlight with their swift-moving ProteoNex™ platform. Forget about sticking samples through sluggish labs and waiting an eternity; eGlint's tech is flipping the switch, serving up protein...

Continue Reading
Alpha Rising Joins RFP: A Strong AI-Fueled Expansion

Updated Category News Views 13

The Shift: From LPL to AI-Driven Innovation Hold onto your hats, because Alpha Rising Wealth Management has taken a significant leap from the traditional ship of LPL Financial to the cutting-edge shores of Rothschild Financial Partners (RFP). It's a move that's painting the walls in Scottsdale, Arizona with $250 million in client assets, all set to benefit from a modern,...

Continue Reading
Food Trends Tease: 2027 sofi™ Awards' 75 Finalists

Updated Category News Views 0

The Specialty Food Scene Heats Up Today’s world doesn’t rest when it comes to innovation, and the same goes for the tantalizing realm of specialty foods. Hot off the press, the Specialty Food Association (SFA) just rolled out the red carpet for its 75 finalists in the 2027 sofi™ Awards. These are the future taste shapers set to take center stage at the Winter...

Continue Reading
Navigating AI Laws: A New Era for Privacy & Security

Updated Category News Views 0

Crucial Insights from the Convergence Conference Rich with intrigue, the privacy and AI governance game just upped its stakes. If there ever was a time to listen closely, it's now, people. With over 150 laws sprouting up faster than weeds, businesses are getting squeezed to keep their artificial ducks in a row. Last month over in New York, some big names in law and...

Continue Reading
GELITA Showcases Collagen Innovations at SupplySide 2026

Updated Category News Views 10

Collagen Solutions Front and Center First up, a little chat about collagen might be in order. For folks not tied into the science side, it sounds like a trendy wellness potion. But here comes GELITA at SupplySide Global 2026, showing it's the real McCoy. Nestled in Booth #4565, they're laying out a spread of next-gen collagen innovations aimed at everything from wound...

Continue Reading
Clean Power Alliance's Bond Deal Secures $91M Savings

Updated Category News Views 0

CPA Triumphs Yet Again With Bond Savings I'll tell you, the Clean Power Alliance (CPA) just hit the jackpot again. We're talking a $1.4 billion energy prepayment bond deal that locks in a whopping $91.1 million in savings over the next seven years. Not bad, huh? A Closer Look at the Numbers CPA's charm—besides being the top green power supplier in the U.S.—is spinning...

Continue Reading

Top 5 Most Recently Viewed Articles

Stem, Inc. Unveils New Strategy Focused on Software and Services

Updated Category News Views 71

Stem, Inc. got serious back in 2024, pivoting hard toward a software and services strategy in the clean energy space. Traders were buzzing when they announced this change—after all, it was all about ditching the heavy hardware resale model that had tied them down like an anchor. Software Shift: The Game-Changer for Stem? The move to a software-centric approach marked a...

Continue Reading
CN Achieves Record Grain Movement in September 2025

Updated Category News Views 154

CN Reports Record Grain Movement In a remarkable achievement, CN (NYSE: CNI) announced its new record for grain movement in September. The company successfully transported over 2.91 million metric tonnes of grain from Western Canada, surpassing its previous record by 80,000 metric tonnes. This achievement underscores CN's commitment to maintaining efficiency and...

Continue Reading
1st Colonial Bancorp Unveils Strategic Stock Buyback Plan

Updated Category News Views 119

1st Colonial Bancorp's Stock Repurchase Program Explained 1st Colonial Bancorp, Inc. (FCOB), the parent company of 1st Colonial Community Bank, recently approved a stock repurchase program aimed at supporting its shareholders and reinforcing confidence in its financial outlook. The company's board of directors has authorized the repurchase of up to 3% of its outstanding...

Continue Reading
Close-Up International Expands in U.S. Market with Acquisition

Updated Category News Views 217

Close-Up International Strengthens Its U.S. Market Position Close-Up International, a leader in AI-powered Customer Relationship Management (CRM) solutions for the pharmaceutical industry, has made a significant move by acquiring MobileDotRep. This strategic acquisition aims to enhance Close-Up's foothold in the U.S. market, positioning them as a formidable competitor...

Continue Reading
Tesla Achieves Record Deliveries and Production in Q4 2024

Updated Category News Views 995

Tesla's Unmatched Performance in Q4 2024 In a significant achievement for the automotive industry, Tesla reported outstanding milestones in the fourth quarter of 2024. The company produced approximately 459,000 vehicles and delivered over 495,000 units, alongside deploying a remarkable 11.0 GWh of energy storage products. This performance sets new records not only for...

Continue Reading